Recent developments in the treatment of sexually transmitted diseases
Recent changes in the treatment of sexually transmitted diseases include recognition of penicillin-resistant Neisseria gonorrhoeae identification of Chlamydia trachomatis as the leading cause of bacterial genital infection in the United States, and the realization that the urethritis syndrome is oft...
Gespeichert in:
| Veröffentlicht in: | The American journal of medicine 1991-12, Vol.91 (6), p.S140-S144 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S144 |
|---|---|
| container_issue | 6 |
| container_start_page | S140 |
| container_title | The American journal of medicine |
| container_volume | 91 |
| creator | Mogabgab, William J. |
| description | Recent changes in the treatment of sexually transmitted diseases include recognition of penicillin-resistant
Neisseria gonorrhoeae identification of
Chlamydia trachomatis as the leading cause of bacterial genital infection in the United States, and the realization that the urethritis syndrome is often associated with multiple pathogens. There is currently no monotherapy that eradicates all STD pathogens. The role of fluoroquinolones in the treatment of STDs is still evolving. The investigational agent, temafloxacin, has good activity against gonococci, nongonococcal organisms, and, unlike other quinolones, against
Bacteroides fragilis and other anaerobes. Norfloxacin, ciprofloxacin, enoxacin, ofloxacin, and temafloxacin single-dose therapy have demonstrated clinical efficacy for gonococcal infections in non-comparative and comparative trials, including bacterial eradication of isolates resistant to other agents. |
| doi_str_mv | 10.1016/0002-9343(91)90327-T |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72602279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>000293439190327T</els_id><sourcerecordid>72602279</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-15a08bfc6523423cca37ae66c8a4bb33b353c1630a82d8ebf026bb6c4584c61b3</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotVbfQGFWoovRXCbJzEaQUi9QEKSuQ5I5g5G51CQt9u2dcYruXJ3bf_7D-RA6J_iGYCJuMcY0LVjGrgpyXWBGZbo6QFPCOU8lEfQQTX8lx-gkhI--xAUXEzQhUsgc0ylavIKFNiYlbKHu1k2fh8S1SXyHJHrQcegkXZUE-Nrout71Xd2GxsUIZVK6ADpAOEVHla4DnO3jDL09LFbzp3T58vg8v1-mlnEZU8I1zk1lBacso8xazaQGIWyuM2MYM4wzSwTDOqdlDqbCVBgjbMbzzApi2Axdjr5r331uIETVuGChrnUL3SYoSQWmVBa9MBuF1ncheKjU2rtG-50iWA301IBGDWhUQdQPPbXq1y72_hvTQPm3NOLq53fjHPontw68CtZBa6F0HmxUZef-P_ANulJ_Cg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72602279</pqid></control><display><type>article</type><title>Recent developments in the treatment of sexually transmitted diseases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Mogabgab, William J.</creator><creatorcontrib>Mogabgab, William J.</creatorcontrib><description>Recent changes in the treatment of sexually transmitted diseases include recognition of penicillin-resistant
Neisseria gonorrhoeae identification of
Chlamydia trachomatis as the leading cause of bacterial genital infection in the United States, and the realization that the urethritis syndrome is often associated with multiple pathogens. There is currently no monotherapy that eradicates all STD pathogens. The role of fluoroquinolones in the treatment of STDs is still evolving. The investigational agent, temafloxacin, has good activity against gonococci, nongonococcal organisms, and, unlike other quinolones, against
Bacteroides fragilis and other anaerobes. Norfloxacin, ciprofloxacin, enoxacin, ofloxacin, and temafloxacin single-dose therapy have demonstrated clinical efficacy for gonococcal infections in non-comparative and comparative trials, including bacterial eradication of isolates resistant to other agents.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/0002-9343(91)90327-T</identifier><identifier>PMID: 1767802</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>4-Quinolones ; Anti-Infective Agents - therapeutic use ; Gonorrhea - drug therapy ; Humans ; Sexually Transmitted Diseases, Bacterial - drug therapy</subject><ispartof>The American journal of medicine, 1991-12, Vol.91 (6), p.S140-S144</ispartof><rights>1991</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-15a08bfc6523423cca37ae66c8a4bb33b353c1630a82d8ebf026bb6c4584c61b3</citedby><cites>FETCH-LOGICAL-c357t-15a08bfc6523423cca37ae66c8a4bb33b353c1630a82d8ebf026bb6c4584c61b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0002-9343(91)90327-T$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1767802$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mogabgab, William J.</creatorcontrib><title>Recent developments in the treatment of sexually transmitted diseases</title><title>The American journal of medicine</title><addtitle>Am J Med</addtitle><description>Recent changes in the treatment of sexually transmitted diseases include recognition of penicillin-resistant
Neisseria gonorrhoeae identification of
Chlamydia trachomatis as the leading cause of bacterial genital infection in the United States, and the realization that the urethritis syndrome is often associated with multiple pathogens. There is currently no monotherapy that eradicates all STD pathogens. The role of fluoroquinolones in the treatment of STDs is still evolving. The investigational agent, temafloxacin, has good activity against gonococci, nongonococcal organisms, and, unlike other quinolones, against
Bacteroides fragilis and other anaerobes. Norfloxacin, ciprofloxacin, enoxacin, ofloxacin, and temafloxacin single-dose therapy have demonstrated clinical efficacy for gonococcal infections in non-comparative and comparative trials, including bacterial eradication of isolates resistant to other agents.</description><subject>4-Quinolones</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Gonorrhea - drug therapy</subject><subject>Humans</subject><subject>Sexually Transmitted Diseases, Bacterial - drug therapy</subject><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMotVbfQGFWoovRXCbJzEaQUi9QEKSuQ5I5g5G51CQt9u2dcYruXJ3bf_7D-RA6J_iGYCJuMcY0LVjGrgpyXWBGZbo6QFPCOU8lEfQQTX8lx-gkhI--xAUXEzQhUsgc0ylavIKFNiYlbKHu1k2fh8S1SXyHJHrQcegkXZUE-Nrout71Xd2GxsUIZVK6ADpAOEVHla4DnO3jDL09LFbzp3T58vg8v1-mlnEZU8I1zk1lBacso8xazaQGIWyuM2MYM4wzSwTDOqdlDqbCVBgjbMbzzApi2Axdjr5r331uIETVuGChrnUL3SYoSQWmVBa9MBuF1ncheKjU2rtG-50iWA301IBGDWhUQdQPPbXq1y72_hvTQPm3NOLq53fjHPontw68CtZBa6F0HmxUZef-P_ANulJ_Cg</recordid><startdate>19911230</startdate><enddate>19911230</enddate><creator>Mogabgab, William J.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19911230</creationdate><title>Recent developments in the treatment of sexually transmitted diseases</title><author>Mogabgab, William J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-15a08bfc6523423cca37ae66c8a4bb33b353c1630a82d8ebf026bb6c4584c61b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>4-Quinolones</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Gonorrhea - drug therapy</topic><topic>Humans</topic><topic>Sexually Transmitted Diseases, Bacterial - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mogabgab, William J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mogabgab, William J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent developments in the treatment of sexually transmitted diseases</atitle><jtitle>The American journal of medicine</jtitle><addtitle>Am J Med</addtitle><date>1991-12-30</date><risdate>1991</risdate><volume>91</volume><issue>6</issue><spage>S140</spage><epage>S144</epage><pages>S140-S144</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><abstract>Recent changes in the treatment of sexually transmitted diseases include recognition of penicillin-resistant
Neisseria gonorrhoeae identification of
Chlamydia trachomatis as the leading cause of bacterial genital infection in the United States, and the realization that the urethritis syndrome is often associated with multiple pathogens. There is currently no monotherapy that eradicates all STD pathogens. The role of fluoroquinolones in the treatment of STDs is still evolving. The investigational agent, temafloxacin, has good activity against gonococci, nongonococcal organisms, and, unlike other quinolones, against
Bacteroides fragilis and other anaerobes. Norfloxacin, ciprofloxacin, enoxacin, ofloxacin, and temafloxacin single-dose therapy have demonstrated clinical efficacy for gonococcal infections in non-comparative and comparative trials, including bacterial eradication of isolates resistant to other agents.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>1767802</pmid><doi>10.1016/0002-9343(91)90327-T</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9343 |
| ispartof | The American journal of medicine, 1991-12, Vol.91 (6), p.S140-S144 |
| issn | 0002-9343 1555-7162 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72602279 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | 4-Quinolones Anti-Infective Agents - therapeutic use Gonorrhea - drug therapy Humans Sexually Transmitted Diseases, Bacterial - drug therapy |
| title | Recent developments in the treatment of sexually transmitted diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A45%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20developments%20in%20the%20treatment%20of%20sexually%20transmitted%20diseases&rft.jtitle=The%20American%20journal%20of%20medicine&rft.au=Mogabgab,%20William%20J.&rft.date=1991-12-30&rft.volume=91&rft.issue=6&rft.spage=S140&rft.epage=S144&rft.pages=S140-S144&rft.issn=0002-9343&rft.eissn=1555-7162&rft_id=info:doi/10.1016/0002-9343(91)90327-T&rft_dat=%3Cproquest_cross%3E72602279%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72602279&rft_id=info:pmid/1767802&rft_els_id=000293439190327T&rfr_iscdi=true |